Apellis Pharmaceuticals ($APLS) has been mentioned 8 times by 4 distinct FinTwit voices over the past 12 months, with the first mention occurring on September 25, 2025. The most recent activity came on April 20, 2026. @ssi_invest (Special Situation Investments) is the most active voice discussing the stock, accounting for 4 of the 8 mentions, followed by @adamfeuerstein with 2 mentions, while @jonerlichman and @tradableastro each contributed 1 mention. The discussion has primarily centered on merger arbitrage situational dynamics.

Most recent developments tracked by these voices indicate that on March 31, 2026, the deal was announced with a contingent value right (CVR) of up to $4 tied to SYFOVRE sales milestones. By April 14, 2026, the tender offer commenced with an expiration date of May 13, 2026. As of April 15, 2026, @ssi_invest noted that CVR optionality remains available despite the tender offer being underway.